Search

Heron Therapeutics Inc

Abierto

SectorSanidad

0.49

Resumen

Variación precio

24h

Actual

Mínimo

0.48

Máximo

0.5

Métricas clave

By Trading Economics

Ingresos

-5.2M

-8.1M

Ventas

-5.9M

35M

BPA

-0.04

Margen de beneficios

-23.367

Empleados

128

EBITDA

-6.8M

-7.6M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+308.16% upside

Dividendos

By Acuity

Próximas Ganancias

10 ago 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-143M

87M

Apertura anterior

0.49

Cierre anterior

0.49

Noticias sobre sentimiento de mercado

By Acuity

19%

81%

34 / 340 Clasificación en Healthcare

Heron Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

29 jul 2026, 23:56 UTC

News

Industrial Logistics Properties Trust shares declined after second-quarter results missed expectations, reporting a loss of -$0.22 per share and revenue of $114.12 million.

29 jul 2026, 23:56 UTC

News

Adobe shares rose after-market, reaching about $263.62. Elevated options volume and a lower put/call ratio reflect bullish sentiment.

29 jul 2026, 23:56 UTC

News

Logitech International SA's quarterly report filing has led to shares trading higher in after-market hours, reflecting increased investor interest.

29 jul 2026, 23:52 UTC

Social Media
News

Robinhood Markets reported record Q2 revenue of $1.31 billion but shares are lower in after-market trading due to a drop in cryptocurrency revenue and revised expense outlook.

29 jul 2026, 23:51 UTC

Social Media
Correlated Moves
News

Hecla Mining reported positive Q2 exploration results, extending high-grade mineralization at Keno Hill and Midas. Shares are higher in after-market trading.

29 jul 2026, 23:51 UTC

Social Media
News

PennyMac Mortgage Investment Trust's Q2 EPS of $0.23 missed estimates, with revenue at $73 million. Shares are trading lower in after-market hours.

29 jul 2026, 23:51 UTC

News

Five9 Inc will join the S&P SmallCap 600 index, effective August 3, 2026. Shares are higher in after-market trading following the announcement.

29 jul 2026, 23:51 UTC

News

General Motors Co shares declined in after-market hours as Ford's strong earnings and guidance overshadowed its outlook amid broader market pressures.

29 jul 2026, 23:51 UTC

Social Media
News

American Water Works reported strong Q2 earnings and revenue but shares declined slightly in after-market hours, reflecting broader market trends.

29 jul 2026, 23:46 UTC

Social Media
News

DoorDash Inc launches DoorDash Air, a new drone delivery unit. Shares are higher in after-market trading, continuing recent upward momentum.

29 jul 2026, 23:46 UTC

News

Avis Budget Group reported second-quarter earnings below expectations, with revenue at $3 billion and EPS of $0.98. Shares are lower in after-market hours.

29 jul 2026, 23:46 UTC

News
Correlated Moves

Entegris Inc. announced board changes, with Bertrand Loy retiring in 2026. Shares are higher in after-market hours, reflecting a broader Nasdaq 100 increase.

29 jul 2026, 23:41 UTC

News

Claros Mortgage Trust reported a second-quarter net loss of $255.4 million, contributing to a decline in after-market trading. Shares are lower.

29 jul 2026, 23:41 UTC

News

ImmunityBio receives UAE marketing authorization for ANKTIVA®, expanding its reach to 34 countries. Shares are trading higher in after-market hours following the announcement.

29 jul 2026, 23:41 UTC

Social Media
News

Corcept Therapeutics shares are trading higher in after-market hours following strong second-quarter results, with revenue of $256.1 million and raised full-year guidance.

29 jul 2026, 23:41 UTC

News

Churchill Downs shares fell after reporting Q2 adjusted EPS of $3.45, slightly missing estimates, and announcing plans to explore property sales.

29 jul 2026, 23:41 UTC

Social Media
News

Meta Platforms reported second-quarter earnings below expectations, with net income declining to $15.85 billion. Shares fell sharply in after-market trading amid rising costs.

29 jul 2026, 23:41 UTC

Social Media
News

Qualcomm Inc shares fell in after-market trading following weaker-than-expected guidance and a profit decline in its third-quarter fiscal 2026 results.

29 jul 2026, 23:41 UTC

Social Media
News

Modine Manufacturing reported first-quarter net income of $73.9 million, but shares declined in after-market trading following mixed results and revenue that missed estimates.

29 jul 2026, 23:36 UTC

News

Antero Resources shares are lower in after-market trading following a second-quarter earnings report that included an adjusted EPS miss and mixed operational results.

29 jul 2026, 23:36 UTC

News

Peabody Energy announced a quarterly dividend of $0.075 per share after reporting $1 billion in revenue, despite a net loss of $90.6 million. Shares rose in after-market trading.

29 jul 2026, 23:32 UTC

News

Invitation Homes reported strong Q2 results, with net income rising to $218.2 million. Shares are trading higher in after-market hours following the earnings report.

29 jul 2026, 23:32 UTC

News

AXT Inc secures an $87 million supply agreement with Lumentum for indium phosphide wafers, boosting its strategic position in the semiconductor market during after-market hours.

29 jul 2026, 23:31 UTC

News

Saia Inc shares are higher in after-market trading as the company prepares to report earnings. It exceeded revenue expectations with $806.2 million last session.

29 jul 2026, 23:31 UTC

News

DMC Global Inc reported second-quarter sales of $157 million, exceeding estimates. Shares are trading higher in after-market hours following the results.

29 jul 2026, 23:31 UTC

Social Media
News

Lam Research Corp reported strong second-quarter earnings, with adjusted EPS of $1.82 and optimistic guidance for Q3, driving shares higher in after-market trading.

29 jul 2026, 23:31 UTC

News

iShares 7-10 Year Treasury Bond ETF trades lower in after-hours, reflecting market caution amid geopolitical tensions and concerns about rising interest rates and inflation.

29 jul 2026, 23:31 UTC

News

Vanguard Total Bond Market ETF declines in after-market trading amid rising geopolitical tensions and concerns over inflation and interest rates affecting market sentiment.

29 jul 2026, 23:31 UTC

News

RenaissanceRe Holdings increased its share buyback program to $750 million and declared a quarterly dividend of $0.41, driving shares higher in after-market trading.

29 jul 2026, 23:26 UTC

News

Ford Motor Co reported adjusted earnings of $0.42 per share, raising its 2026 guidance and prompting shares to rise in after-market trading.

Comparación entre iguales

Cambio de precio

Heron Therapeutics Inc previsión

Precio Objetivo

By TipRanks

308.16% repunte

Estimación a 12 Meses

Media 2 USD  308.16%

Máximo 2 USD

Mínimo 2 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Heron Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

1

Comprar

1

Mantener

0

Vender

Sentimiento

By Acuity

34 / 340 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
help-icon Live chat